Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Silexion Therapeutics ( (SLXN) ) has shared an announcement.
On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders detailing what it called a transformational 2025, highlighted by strong preclinical data for its lead RNAi asset SIL204, which showed over 90% inhibition of KRAS-mutated cancer cell growth across multiple mutations and tumor types, including pancreatic, colorectal, lung and other solid tumors. During 2025 the company also completed two-species toxicology studies with no systemic organ toxicity observed, received positive guidance from Germany’s BfArM on a planned Phase 2/3 trial design in locally advanced pancreatic cancer, secured manufacturing and clinical development partners, raised more than $18 million in financing and regained full Nasdaq compliance, steps that collectively move SIL204 closer to first-in-human testing and strengthen the firm’s positioning in the emerging pan-KRAS therapy space. Looking ahead, Silexion has completed regulatory submissions in Israel for a Phase 2/3 trial in locally advanced pancreatic cancer and plans additional filings in Germany, other EU countries and the U.S. in 2026, with a trial design that includes a safety run-in in combination with standard chemotherapy followed by a randomized expansion, a program it believes could generate pivotal human data to underpin future partnerships and funding while addressing a major unmet need in KRAS-driven cancers.
The most recent analyst rating on (SLXN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and worsening cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Positive clinical/regulatory updates for SIL204 provide an offsetting catalyst, but valuation remains hard to justify given ongoing losses and no dividend support.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven solid tumors, including pancreatic, colorectal and lung cancers, targeting what it estimates to be a more than $30 billion global market. The company’s lead candidate, SIL204, builds on earlier positive Phase 2a data from a first-generation product and is being advanced primarily for locally advanced pancreatic cancer, with strategic manufacturing and clinical collaborations in place and its shares listed on Nasdaq under the ticker SLXN.
Average Trading Volume: 63,097
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.88M
Learn more about SLXN stock on TipRanks’ Stock Analysis page.